CTI(SZ:300012)2024-01-18 09:47Financial Performance - The company achieved an annual revenue range of CNY 5.541 billion to CNY 5.695 billion, representing a year-on-year growth of 8% [1] - The net profit attributable to shareholders is projected to be between CNY 904 million and CNY 921 million, with a year-on-year growth of 0.2% to 2% [1] - Excluding one-time business impacts, the overall revenue maintained double-digit growth in 2023 [1] Segment Performance - The decline in the pharmaceutical and medical segment significantly impacted overall profits, while other business segments maintained double-digit net profit growth when excluding this segment [1] - The life sciences segment showed stable growth, with strong performance in consumer goods and industrial testing, particularly in automotive and electronic technology [1] - ESG and digital business segments continued to show positive trends, and the trade assurance segment experienced overall growth [1] Strategic Outlook - Management plans to set reasonable growth targets based on external environmental trends and the actual situation of 2023, aiming for stable profit margins with slight improvements [1] - The company is actively seeking potential acquisition opportunities, focusing on different product lines and sectors to capture new growth opportunities in the rapidly developing testing and certification industry in China [2]